Novo Nordisk's long game on weight loss drugs sparks hope in science, but the Street is impatient Novo Nordisk has had a ...

Novo Nordisk is lowering prices of its top-selling obesity drug Wegovy in China, the Danish drugmaker said on Monday, as it ...

Novo Nordisk’s oral Wegovy gets FDA approval, but rising costs and competition threaten profits. Learn why analysts rate NVO ...

Novo Nordisk plans to sell its newly approved obesity pill directly to patients at a lower price than a competing medicine ...

The U.S. Food and Drug Administration has approved Novo Nordisk’s Wegovy® pill, making it the first and only oral GLP-1 ...

Omeros transitions from a distressed microcap to a small-cap following a transformative Novo Nordisk deal and FDA approval of ...

Chautauqua Capital Management, a division of Baird Asset Management, is a boutique investment firm that released its third ...

Novo Nordisk and Eli Lilly are significantly lowering prices of their blockbuster obesity drugs Wegovy and Mounjaro in China, ...

The U.S. Food and Drug Administration on Dec. 22 approved a pill version of Novo Nordisk’s weight-loss drug Wegovy.

The pharmaceutical giant's stock has tumbled over the past year and a half, but it could be poised to storm back.

Novo Nordisk A/S (NYSE:NVO) is a global healthcare company specializing in diabetes care. It develops, discovers, ...

Novo Nordisk and Eli Lilly are reducing prices for their widely used obesity medications, Wegovy and Mounjaro, in China, a ...